Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain

Figures & data

Table 1 Estimated Adult Population With SLE With High Disease Activity And Positive Autoantibodies In Spain

	N	References
Spanish adult population	38,128,226	National Institute of Statistics (INE) 2017^Citation13
Population with SLE	34,697	EPISER^Citation14 and systemic auto-immune disease (GEAS) group
Diagnosed with SLE	30,533	Expert panel^Citation15
SLE population without severe active lupus nephritis or severe active CNS lupus	20,610	Adapted from: Somers EC et al 2009^Citation16 and Rúa-Figueroa I et al 2014^Citation17
SLE population with positive autoantibodies and disease activity	12,220	Lupus Monitor^Citation19
SLE population with high disease activity	4277	Adapted from Cervera et al 2013^Citation10
On pharmacological treatment	3849	Expert panel^Citation15

Table 2 Annual Costs Per Patient Associated With Flares According To Severity

Treatment	Cost Of Non-Severe Flares	Cost Of Severe Flares
Belimumab SC + Standard Therapy	€1172.41	€2640.22
Belimumab IV + Standard Therapy	€1172.41	€2640.22
Standard Therapy	€1367.81	€4889.30
Reduction in annual costs	€195.40	€2249.08
Total reduction in annual costs	€2,444.48

Figure 1 Total budget impact of the introduction of belimumab SC in the Spanish NHS.

Table 3 Pharmacological Budget Impact Of The Introduction Of Belimumab SC

	Year 1	Year 2	Year 3
Total number of patients eligible for belimumab	3891	3943	3995
Total patients on belimumab treatment	889 (22.8%)	934 (23.7%)	927 (23.2%)
Scenario without belimumab SC
Belimumab IV + ST	€11,002,596.27	€11,568,022.00	€11,481,887.90
Standard Therapy	€1,693,285.12	€1,716,054.31	€1,738,631.99
Total	€12,695,881.38	€13,284,076.31	€13,220,519.90
Scenario with belimumab SC
Belimumab SC + ST	€3,452,758.06	€6,763,692.63	€7,932,655.42
Belimumab IV + ST	€7,385,521.46	€4,482,603.39	€3,172,082.01
Standard Therapy	€1,693,285.12	€1,716,054.31	€1,738,631.99
Total	€12,531,564.63	€12,962,350.33	€12,843,369.43
Net Impact	- €164,316.75	- €321,725.98	- €377,150.47

Abbreviation: ST, standard therapy.

Figure 2 Tornado diagram: univariate sensitivity analysis.

INE. Resident population by date, sex and age. National results. Inst Nac Statistics 2017

 Google Scholar

Spanish Society of Rheumatology. Episer studio. Available from: http://www.ser.es/episer/ Accessed 1025, 2019.

 Google Scholar

Cevey M, Calvo-Alén J, Crespo C, Robles-Marhuenda A, Cortés J. Systemic lupus erythematosus in Spain in patients with high activity of the disease in the next 5 years. Reumatol Clin. 2018;14(Spec Cong):28–286.

 Google Scholar

Somers EC, Marder W, Lewis EE, et al. Michigan Lupus Epidemiology & Surveillance Program (MILES): increased proportion of target-organ threatening involvement among male versus female SLE patients In: American College of Rheumatology ACR-ARP Annual Meeting. Philadelphia (PA); 2009:235 [Abstract # 302].

 Google Scholar

Rúa-Figueroa Í, Richi P, López-Longo FJ, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Med (United States). 2015;94(1):e267. doi:10.1097/MD.0000000000000267

 Web of Science ®Google Scholar

Ipsos Healthcare. Lupus Monitor market research 2016. Madrid 2017

 Google Scholar

Cervera R, Rúa-Figueroa I, Gil-Aguado A, et al. Direct cost of management and treatment of active systemic lupus erythematosus and its outbreaks in Spain: the LUCIE Study. Rev Clin Esp. 2013;213(3):127–137. doi:10.1016/j.rce.2012.11.01823398815

 PubMedGoogle Scholar